FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028011730> ?p ?o ?g. }

• W2028011730 endingPage "565" @default.
• W2028011730 startingPage "565" @default.
• W2028011730 abstract "In a recent issue of the American Journal of Medicine, Passamonti et al reported a significantly higher mortality for polycythemia vera (PV) patients than in a sex-, age-, and calendar year-matched Italian general population in a retrospective analysis of 396 PV patients, using standardized mortality ratio (SMR).1Passamonti F. Rumi E. Pungolino E. et al.Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.Am J Med. 2004; 117: 755-761Abstract Full Text Full Text PDF PubMed Scopus (373) Google Scholar Thrombosis was the most frequent complication and the main cause of death, and a history of thrombosis was the only adverse prognostic factor for survival. By contrast, survival of patients with essential thrombocythemia was similar to that of the general population. We previously published the final analysis of a prospective study that enrolled 179 PV patients with the longest mean follow-up reported to date of 11.4 years.2Kiladjian J.J. Gardin C. Renoux M. Bruno F. Bernard J.F. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.Hematol J. 2003; 4: 198-207Crossref PubMed Scopus (50) Google Scholar In our study, SMR for the entire cohort, as well as for the different age and sex subgroups, were not statistically different from those of the French population. We also found that hyperleukocytosis was a significant risk factor for evolution to leukemia and shortened survival. A trend for such unfavorable impact of hyper leukocytosis on leukemic evolution (P = 0.065) was also reported in the recent analysis of the European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) prospective study.3Finazzi G. Caruso V. Marchioli R. et al.Acute leukemia in polycythemia vera. An analysis of 1638 patients enrolled in a prospective observational study.Blood. 2005; 105: 2664-2670Crossref PubMed Scopus (350) Google Scholar Reaching a balance between the vascular risk and the possible leukemogenicity of cytoreductive treatments is a major aim in the therapeutic strategy of PV. Evaluation of life expectancy of PV patients, identification of prognostic factors, and precise determination of very long-term complications are crucial for the management of this long-lasting disease. In our study, the incidence of thrombosis (15% at 10 years) was even lower than observed in the French matched-control population, showing that a careful management of PV might reduce the vascular risk associated with the disease. All our patients had been homogeneously treated with a cytoreductive agent (pipobroman) with a very high response rate of 98%. In the Passamonti et al study, various therapeutic strategies were used and the response rate was not documented, making difficult the interpretation of the high incidence of thrombosis reported. Furthermore, the somewhat shorter follow-up (9.6 years versus 11.4 years in our study), the smaller number of deaths observed (33% compared to 54% in our study), and the retrospective nature of their study could have biased the data obtained. Finally, controversies concerning outcome of patients with myeloproliferative disorders stress the need for long-term data obtained from prospective studies in chronic malignancies that cannot be cured with currently available drugs. The replyThe American Journal of MedicineVol. 118Issue 5PreviewKiladjian et al state that the results of their study showed a standardized mortality ratio (SMR) of 1.0 and a 15-year risk of thrombosis of 21.8% in 164 polycythemic patients.1 In our cohort of 396 patients with polycythemia vera, SMR was 1.6 and the 15-year risk of thrombosis was 27%.2 Full-Text PDF" @default.
• W2028011730 created "2016-06-24" @default.
• W2028011730 creator A5008609620 @default.
• W2028011730 creator A5014838075 @default.
• W2028011730 creator A5017908203 @default.
• W2028011730 date "2005-05-01" @default.
• W2028011730 modified "2023-10-01" @default.
• W2028011730 title "Is life expectancy of polycythemia vera patients clearly different from that of the general population?" @default.
• W2028011730 cites W191251843 @default.
• W2028011730 cites W1998721150 @default.
• W2028011730 cites W2010740179 @default.
• W2028011730 cites W2112316414 @default.
• W2028011730 doi "https://doi.org/10.1016/j.amjmed.2004.12.026" @default.
• W2028011730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15866263" @default.
• W2028011730 hasPublicationYear "2005" @default.
• W2028011730 type Work @default.
• W2028011730 sameAs 2028011730 @default.
• W2028011730 citedByCount "0" @default.
• W2028011730 crossrefType "journal-article" @default.
• W2028011730 hasAuthorship W2028011730A5008609620 @default.
• W2028011730 hasAuthorship W2028011730A5014838075 @default.
• W2028011730 hasAuthorship W2028011730A5017908203 @default.
• W2028011730 hasBestOaLocation W20280117301 @default.
• W2028011730 hasConcept C126322002 @default.
• W2028011730 hasConcept C133925201 @default.
• W2028011730 hasConcept C167135981 @default.
• W2028011730 hasConcept C187212893 @default.
• W2028011730 hasConcept C2778837598 @default.
• W2028011730 hasConcept C2778923028 @default.
• W2028011730 hasConcept C2780007613 @default.
• W2028011730 hasConcept C2780076729 @default.
• W2028011730 hasConcept C2781057849 @default.
• W2028011730 hasConcept C2908647359 @default.
• W2028011730 hasConcept C71924100 @default.
• W2028011730 hasConcept C72563966 @default.
• W2028011730 hasConcept C99454951 @default.
• W2028011730 hasConceptScore W2028011730C126322002 @default.
• W2028011730 hasConceptScore W2028011730C133925201 @default.
• W2028011730 hasConceptScore W2028011730C167135981 @default.
• W2028011730 hasConceptScore W2028011730C187212893 @default.
• W2028011730 hasConceptScore W2028011730C2778837598 @default.
• W2028011730 hasConceptScore W2028011730C2778923028 @default.
• W2028011730 hasConceptScore W2028011730C2780007613 @default.
• W2028011730 hasConceptScore W2028011730C2780076729 @default.
• W2028011730 hasConceptScore W2028011730C2781057849 @default.
• W2028011730 hasConceptScore W2028011730C2908647359 @default.
• W2028011730 hasConceptScore W2028011730C71924100 @default.
• W2028011730 hasConceptScore W2028011730C72563966 @default.
• W2028011730 hasConceptScore W2028011730C99454951 @default.
• W2028011730 hasIssue "5" @default.
• W2028011730 hasLocation W20280117301 @default.
• W2028011730 hasLocation W20280117302 @default.
• W2028011730 hasOpenAccess W2028011730 @default.
• W2028011730 hasPrimaryLocation W20280117301 @default.
• W2028011730 hasRelatedWork W1978226762 @default.
• W2028011730 hasRelatedWork W1983772871 @default.
• W2028011730 hasRelatedWork W2028131386 @default.
• W2028011730 hasRelatedWork W2078182058 @default.
• W2028011730 hasRelatedWork W2081259800 @default.
• W2028011730 hasRelatedWork W2135883201 @default.
• W2028011730 hasRelatedWork W2314663195 @default.
• W2028011730 hasRelatedWork W2562937924 @default.
• W2028011730 hasRelatedWork W2571353949 @default.
• W2028011730 hasRelatedWork W4311576476 @default.
• W2028011730 hasVolume "118" @default.
• W2028011730 isParatext "false" @default.
• W2028011730 isRetracted "false" @default.
• W2028011730 magId "2028011730" @default.
• W2028011730 workType "article" @default.